EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells

Ian-Ian Ng, Jiaqi Zhang, Tingzhong Tian, Qi Peng, Zheng Huang, Kaimin Xiao, Xiyue Yao, Lui Ng, Jianyang Zeng, Haidong Tang iD

Journal for ImmunoTherapy of Cancer · 2024-03 · 12 (3) · e008254

DOI: 10.1136/jitc-2023-008254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.03.2024. Verfasst von Ian-Ian Ng und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Tsinghua-Toyota Joint Research Fund, Tsinghua-Peking University Center for Life Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dendritic cell (DC)-mediated antigen presentation is essential for the priming and activation of tumor-specific T cells. However, few drugs that specifically manipulate DC functions are available. The identification of drugs targeting DC holds great promise for cancer immunotherapy.

Methods

We observed that type 1 conventional DCs (cDC1s) initiated a distinct transcriptional program during antigen presentation. We used a network-based approach to screen for cDC1-targeting therapeutics. The antitumor potency and underlying mechanisms of the candidate drug were investigated in vitro and in vivo.

Results

Sitagliptin, an oral gliptin widely used for type 2 diabetes, was identified as a drug that targets DCs. In mouse models, sitagliptin inhibited tumor growth by enhancing cDC1-mediated antigen presentation, leading to better T-cell activation. Mechanistically, inhibition of dipeptidyl peptidase 4 (DPP4) by sitagliptin prevented the truncation and degradation of chemokines/cytokines that are important for DC activation. Sitagliptin enhanced cancer immunotherapy by facilitating the priming of antigen-specific T cells by DCs. In humans, the use of sitagliptin correlated with a lower risk of tumor recurrence in patients with colorectal cancer undergoing curative surgery.

Conclusions

Our findings indicate that sitagliptin-mediated DPP4 inhibition promotes antitumor immune response by augmenting cDC1 functions. These data suggest that sitagliptin can be repurposed as an antitumor drug targeting DC, which provides a potential strategy for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2NeoplasmsAntineoplastic AgentsMiceAnimalsHumansDipeptidyl Peptidase 4Dendritic CellsSitagliptin PhosphateAntigen Presentation

Stichwörter der Autor:innen

Antigen PresentationDendritic CellsDrug Evaluation, PreclinicalImmunotherapyTumor Microenvironment

Substanzen

Dipeptidyl Peptidase 4Sitagliptin PhosphateAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Molecular Oncology, School of Pharmaceutical Sciences, Tsinghua University, Beijing, China.
  • Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China.
  • Joint Graduate Program of Peking-Tsinghua-NIBS, School of Life Sciences, Tsinghua University, Beijing, China.
  • Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China hdtang@tsinghua.edu.cn zengjy321@tsinghua.edu.cn luing@hku.hk.
  • Institute for Interdisciplinary Information Sciences, Tsinghua University, Beijing, China hdtang@tsinghua.edu.cn zengjy321@tsinghua.edu.cn luing@hku.hk.

ORCID-Profile: Haidong Tang

Förderung

  • National Natural Science Foundation of China
  • Tsinghua-Toyota Joint Research Fund
  • Tsinghua-Peking University Center for Life Sciences
  • Turing AI Institute of Nanjing
  • National Key Research and Development Program of China
  • National Youth Talent Support Program
  • Health and Medical Research Fund of the Research Fund Secretariat, Food and Health Bureau, HKSAR

Zitieren

APA

Ng, I. I., Zhang, J., Tian, T., Peng, Q., Huang, Z., Xiao, K., Yao, X., Ng, L., Zeng, J., & Tang, H. (2024). Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells. Journal for ImmunoTherapy of Cancer, 12(3), e008254. https://doi.org/10.1136/jitc-2023-008254

Vancouver

Ng II, Zhang J, Tian T, Peng Q, Huang Z, Xiao K, et al. Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells. Journal for ImmunoTherapy of Cancer. 2024;12(3):e008254. doi:10.1136/jitc-2023-008254

BibTeX
@article{Ng2024,
  author = {Ng, Ian-Ian and Zhang, Jiaqi and Tian, Tingzhong and Peng, Qi and Huang, Zheng and Xiao, Kaimin and Yao, Xiyue and Ng, Lui and Zeng, Jianyang and Tang, Haidong},
  title = {Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {3},
  pages = {e008254},
  doi = {10.1136/jitc-2023-008254}
}
Kostenlos starten →